Abstract:Background: Liver hepatocellular carcinoma (LIHC), one of the most common primary malignancies, exhibits high levels of molecular and clinical heterogeneity. Increasing evidence has confirmed the important roles of some RNA helicase families in tumor development, but the function of the DEAH-box RNA helicase family in LIHC therapeutic strategies has not yet been clarified. Methods: The LIHC dataset was downloaded from The Cancer Genome Atlas (TCGA). Consensus clustering was applied to group the patients. Least absolute shrinkage and selection operator Cox regression and univariate and multivariate Cox regression were used to develop and validate a prognostic risk model. The Tumor Immune Estimation Resource and Tumor Immune Single Cell Hub databases were used to explore the role of DEAH-box RNA helicases in LIHC immunotherapy. In vitro experiments were performed to investigate the role of DHX9 in LIHC radiosensitivity. Results: Twelve survival-related DEAH-box RNA helicases were identified. High helicase expression levels were associated with a poor prognosis and clinical features. A prognostic model comprising six DEAH-box RNA helicases (DHX8, DHX9, DHX34, DHX35, DHX38, and DHX57) was constructed. The risk score of this model was found to be an independent prognostic indicator, and LIHC patients with different prognosis were distinguished by the model in the training and test cohorts. DNA damage repair pathways were also enriched in patients with high-risk scores. The six DEAH-box RNA helicases in the risk model were substantially related to innate immune cell infiltration and immune inhibitors. In vitro experiments showed that DHX9 knockdown improved radiosensitivity by increasing DNA damage. Conclusion: The DEAH-box RNA helicase signature can be used as a reliable prognostic biomarker for LIHC. In addition, DHX9 may be a definitive indicator and therapeutic target in radiotherapy and immunotherapy for LIHC.

Supplementary Table from RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1

RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

Transcriptome Sequencing of Hepatocellular Carcinoma Uncovers Multiple Types of Dysregulated Ncrnas

RNA helicase DDX24 stabilizes LAMB1 to promote hepatocellular carcinoma progression

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma

Hnf6 Promotes Tumor Growth In Colorectal Cancer And Enhances Liver Metastasis In Mouse Model

Landscape Analysis of Lncrnas Shows That DDX11-AS1 Promotes Cell-Cycle Progression in Liver Cancer Through the PARP1/p53 Axis

Supplementary files from An LTR Retrotransposon-Derived Long Noncoding RNA lncMER52A Promotes Hepatocellular Carcinoma Progression by Binding p120-Catenin

DHX37 is a Promising Prognostic Biomarker and a Therapeutic Target for Immunotherapy and Chemotherapy in HCC

Aberrant Expression of Circular RNA DHPR Facilitates Tumor Growth and Metastasis by Regulating the RASGEF1B/RAS/MAPK Axis in Hepatocellular Carcinoma

Supplementary Data 1 from an LTR Retrotransposon-Derived Long Noncoding RNA Lncmer52a Promotes Hepatocellular Carcinoma Progression by Binding P120-Catenin

Supplementary Table 4 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis Via Protrusion Formation

Supplementary Tables 8 - 9 from LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act As a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern

High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma

DDX39 Promotes Hepatocellular Carcinoma Growth and Metastasis Through Activating Wnt/β-catenin Pathway

Supplementary Data 3 from an LTR Retrotransposon-Derived Long Noncoding RNA Lncmer52a Promotes Hepatocellular Carcinoma Progression by Binding P120-Catenin

Supplementary Data 2 from an LTR Retrotransposon-Derived Long Noncoding RNA Lncmer52a Promotes Hepatocellular Carcinoma Progression by Binding P120-Catenin